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INTRODUCTION
Candida species are opportunistic agents responsible for various clinical manifestations from mucocutaneous overgrowth to bloodstream infections (Eggimann et al. 2003) . The most frequently isolated Candida species are Candida albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei, respectively, which account for more than 90% of all invasive infections (Pfaller et al. 2007) . The prevalence of invasive Candida infections has dramatically increased in the last decades, particularly in immune compromised and in hospitalized individuals with implanted medical devices (Ramage, Martínez and López-Ribot 2006; Espinel-Ingroff et al. 2009; Mermel et al. 2009 ). In particular, device-associated Candida infections can reach mortality rates of more than 30% (Pappas et al. 2003; Kojic and Darouiche 2004; Kumamoto and Vinces 2005; Nett et al. 2007) . Indeed, the annual cost of antifungal therapies has been estimated in $3 billion only in the USA (Viudes et al. 2002; Sardi et al. 2013) .
It is now well recognized that the majority of diseases caused by Candida are associated with biofilm growth and that indwelling medical devices such as intravascular catheters are major risk factors for candidemia (Ramage et al. 2006; Ramage and Lopez-Ribot 2005) . Candida species can grow as biofilm on almost any type of medical devices, including vascular and urinary catheters, joint prostheses, cardiac valves, artificial vascular bypass devices, pacemakers, ventricular assist devices and central nervous system shunts (Sardi et al. 2013) . Similarly to biofilm-producing pathogenic bacteria, biofilm-growing Candida species are more resistant to antimicrobial agents, often causing treatment failure and the need to remove the infected device (Sardi et al. 2013) . Available techniques for the assessment of biofilm production in Candida are generally material-and time consuming and highly variable in assay performance, reproducibility and costs (Hawser and Douglas 1994; Ramage et al. 2001; Kuhn et al. 2003; Honraet, Goetghebeur and Nelis 2005; Nailis et al. 2006; Chandra, Mukherjee and Ghannoum 2008; Peeters, Nelis and Coenye 2008; Silva et al. 2009; Gobor et al. 2010; Taff, Nett and Andes 2012; Marcos-Zambrano et al. 2014) . Thus, novel tests are necessary to allow for a rapid and reliable laboratory assessment of Candida biofilms feasible for clinical testing. The clinical Biofilm Ring Test (cBRT) has been recently developed to evaluate biofilm in a large spectrum of bacterial species (Di Domenico et al. 2016 . The principle is based on the in vitro immobilization of magnetic microparticles within the biofilm matrix by the growing bacterial cells (Chavant et al. 2007 ). The assay provides an assessment of the ability of the newly produced biofilm to entrap the microparticles within its matrix. This element is an indirect, physical parameter that measures the ability of microbial cells to form biofilm. If a matrix is not sufficiently strong to entrap and hold the microparticles, overcoming the attraction forces exerted by specific magnets, this indirectly defines a weak biofilm producer, while a strong biofilm producer will rapidly and efficiently block the microparticles. Thus, in the absence of a sufficient number of sessile cells, the beads are gathered by the magnet resulting in a spot (ring) easily detectable. This method was found to be rapid and robust in testing microbial biofilm and suitable for high-throughput screening in clinical microbiology (Chavant et al. 2007; Di Domenico et al. 2017) .
This study was aimed at developing a simple, accurate and reproducible protocol, based on the previously described cBRT (Di Domenico et al. 2016) , for the quantitative assessment of biofilm formation by Candida species for clinical application. The original protocol, previously developed for bacterial cells, has been adapted to address the specific physiological requirements of yeast cells, which have a bigger size and an extended doubling time, as compared to bacteria. In the Candida cBRT protocol, the initial inoculum was modified from approximately 1.0 × 10 9 ± 3.6 × 10 8 CFU/mL previously used for bacteria to 6.4 ± 1.4 × 10 6 CFU/mL for Candida species. In addition, the time of incubation has been extended from 5 h used for bacteria to 20 h for the Candida cBRT. The results gathered by the cBRT were compared to those obtained by well-established methods, including the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) reduction assay and crystal violet (CV) assay, respectively (Tellier et al. 1992; Kuhn et al. 2002; Peeters, Nelis and Coenye 2008; Alnuaimi et al. 2013) .
MATERIALS AND METHODS

Clinical and laboratory Candida strains and growth conditions
Candida strains were collected from different biologic samples, including infected ulcerative lesions, intravenous and urinary catheter tips, urine, sputum and bronchial lavage specimens. Individual species and characteristics of the strains are reported in 
Clinical Biofilm Ring Test protocol for Candida species
The test was performed using the reagents provided by the Biofilm Ring Test kit (KITC004) (Biofilm Control, Saint Beauzire, France) and comprising 96-well polystyrene plates (12 columns of 8 wells), the BHI growth medium, a toner solution (magnetic microbeads), contrast liquid (an inert opaque oil used for the reading step), a pack comprising a block test (the magnet support) and a specific scan plate reader (Chavant et al. 2007) .
To assess biofilm formation in Candida, specific modifications were introduced in the cBRT protocol developed for bacteria (Di Domenico et al. 2016) . Specifically, a fresh overnight culture of Candida strain, grown on sabouraud dextrose agar plates with chloramphenicol, was used to inoculate, by a sterile inoculating loop, 3 mL of 0.45% saline solution (AirLife, Carefusion, CA, USA) to the equivalent of 2.5 ± 0. One or more laboratory strains were included in each plate as standard reference and quality control. A well containing the BHI/TON mix without microbial cells was used as negative control in each experiment.
After incubation, wells were covered with 120 μL of contrast liquid (inert opaque oil), and placed for 1 min on the block test. The block test contains 96 magnets centered under the bottom of each well of the 96-well polystyrene plate. After magnet contact, the free microparticles are attracted in the center of the bottom of wells, creating a spot, while the beads entrapped within the biofilm matrix remain in place and are not detectable. Images of each well were collected by a plate reader and bead aggregation was analyzed by the BFC Elements 3.0 software (Biofilm reader, Biofilm Control). The adhesion strength of each Candida strain was expressed as biofilm index (BFI), which was calculated by a dedicated software. The values of BFI were used to measure the biofilm-forming potential (BP), by the formula: BP = [1-(BFI sample/average BFI of negative control)] for each well. The cut-off (BFIc) value was defined as three standard deviations above the mean of the negative control wells. Values of BP above two times the cut-off (2BFIc) were considered to be significant biofilm formers. Thus, the last dilution above 2BFIc identifies the ability of the microorganism to form biofilm. Accordingly, microorganisms were classified into the following categories: weak (BP < 2BFIc at 1 × 10 −1 McF, BP > 2BFIc at 1 × 10 −1 and/or 1 × 10
McF), moderate (BP > 2BFIc at 1 × 10 −3 and/or 1 × 10 −4 McF) and high biofilm producer (BP > 2BFIc at 1 × 10 −5 and/or 1 × 10
McF), respectively. Each yeast culture was analyzed in duplicate and experiments were repeated at least three times for each strain to assess repeatability, accuracy and precision of the assay. Values were considered valid when the standard deviation between duplicates did not exceed 8%. Replicates showed a complete categorical accordance within their classification.
Comparative assessment of biofilm formation by different assays
Biofilm formation was evaluated according to previously described and well-established procedures (Ramage et al. 2001; Kuhn et al. 2002; Pongrácz et al. 2016; Pierce et al. 2010) , with some modifications to allow comparability among the assays in terms of inoculum, time of incubation and evaluation of the results. Briefly, sterile 96-well polystyrene test plates were inoculated with 200 μL of an initial suspension of Candida strains (10 5 CFU/ml) in BHI medium and incubated at 37
• C for 20 h without shaking. After incubation, the medium was removed to discard planktonic cells and the wells were washed three times with sterile distilled water. Cells adhering to the bottom of the wells (biofilm-forming) were quantified by CV and using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl) -5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) reduction assay (Sigma Chemical Co., St. Louis, MO, USA). For the CV, 200 μL sterile distilled water was added to test wells and the level of biofilm production was measured by spectrophotometric readings at 570 nm using the automated microtiter plate reader PhD lx System (Bio-Rad Laboratories, Hercules, CA, USA). In the XTT assay, biofilm was quantified biochemically by treating the prewashed biofilm and control wells with 100 μL of the salt solution (1 mg/ml in PBS) and 1 μM menadione solution (Sigma Chemical Co.) prepared in acetone. The plates were incubated in the dark at 37
• C for 5 h, and the amount of XTT was measured at 490 nm using the plate reader PhD lx System (Bio-Rad Laboratories). For comparative analysis, optical density (OD) values obtained by CV and XTT were used to classify semiquantitatively biofilm production according to the method described in Stepanovic et al. (2000) . Specifically, the cut-off OD (ODc) was defined as three standard deviations above the mean OD of the negative control and strains were classified as follows: OD ≤ 2 × ODc = weak biofilm producer; 2 × ODc < OD < 4 × ODc = moderate biofilm producer; and OD ≥ 4 × ODc = high biofilm producer, respectively.
Candida albicans ATCC 2091, C. albicans ATCC 60193, C. albicans ATCC 10231, C. albicans ATCC 14053, C. albicans ATCC 64548, C. parapsilosis ATCC 22019, C. parapsilosis ATCC 90018 and C. krusei ATCC 6258 were used as controls in each experiment. Additionally, 12 negative control wells, comprising BHI only, were included in each test. Strains and controls were evaluated in triplicate on three different experiments.
Statistical methods
The kappa coefficient test was used to determine the agreement between the results obtained with the Candida cBRT assay as compared to CV and XTT, respectively. The strength of agreement was calculated according to Altman (1991) , considering the following parameters: kappa = 0.81-1, very good; kappa = 0.61-0.80, good; kappa 0 0.41-0.60, moderate; kappa = 0.21-0.40, fair; kappa ≤ 0.20, poor. The results obtained with the different procedures were further compared using the McNemar's test. All P values were two-tailed. P < 0.05 was considered statistically significant.
RESULTS
In preliminary experiments, eight laboratory strains of Candida species obtained from the ATCC collection were grown as biofilms. These strains included five C. albicans and three strains of non-albicans Candida (NAC) species such as two C. parapsilosis and one C. krusei with previously described ability to produce biofilm (Emerson and Camesano 2004; Emira et al. 2011; Rane et al. 2012; Valentín et al. 2012; Alnuaimi et al. 2013; Hsu et al. 2013; Susewind, Lang and Hahnel 2015; Ferreira et al. 2017; Kackar, Suman and Kotian 2017; Kim et al. 2017; Turan and Demirbilek 2018) . After 20 h of incubation, the levels of biofilm production measured by the cBRT were compared with those assessed by CV ad XTT, respectively, which are both considered gold standard methods for biofilm detection in Candida species. A full categorical agreement was considered to be achieved for those isolates classified within the same category with two methods. Achievement of a partial categorical agreement was considered when the results obtained by both CV and XTT differed for one category. Isolates which did not fell in the full or partial categorical agreement were considered as being in disagreement.
Comparative analysis (Table 2) revealed that a full categorical agreement was achieved between cBRT and CV in seven cases out of eight (87.5%). In only one measurement, referring to C. albicans ATCC 14053, a partial categorical agreement was observed, with CV classifying the strain as a moderate biofilm producer while resulting a weak biofilm producer by cBRT. Conversely, a full categorical agreement was observed in six out of eight strains (75%) when comparing the results obtained by cBRT to those gathered by XTT. The remaining two cases of partial categorical agreement (25%) referred to C. albicans ATCC 14053 and C. parapsilosis 90018. The analysis of accordance between CV and XTT revealed a full categorical agreement in seven cases out of eight (87.5%), with only one partial categorical agreement referred to the strain C. parapsilosis 90018, classified as moderate biofilm producer by CV and weak biofilm producer by the XTT assay, respectively. Notably, none of the assessment performed by cBRT, CV and XTT were found to be in disagreement, thus confirming a remarkable level of accordance between cBRT and both CV and XTT methods, respectively.
Biofilm-forming ability of clinical isolates of C. albicans and non-albicans Candida species
A total of 60 Candida clinical isolates, collected from different types of specimens (Table 1) , were assessed by cBRT, CV and XTT, respectively (see Supplementary data). Statistical analysis revealed a high correlation among the different tests (average measures 0.90-95% confidence interval 0.84 to 0.94), with a full accordance in the level of biofilm production with 68% of the strains analyzed. Assessment by the cBRT identified 45% of weak, 30% of moderate and 25% of high biofilm producers, respectively.
Comparative testing by CV gave 40% as weak, 43% as moderate and 17% as high biofilm producers, whereas the XTT metabolic assay gave 35% of weak biofilm producers, 36.7% of moderate and 28.3% of high biofilm producers, respectively (Fig. 2) .
Analysis of the results gathered by cBRT and CV showed a full categorical agreement in 80% of cases (Table 3 ). In the remaining 20% of cases, cBRT and CV exhibited a partial categorical agreement. Notably, none of the 60 strains analyzed by cBRT and CV showed discordant results. Conversely, a full categorical agreement between cBRT and XTT was observed in 72% of cases, with 23% of cases giving a partial categorical agreement. In three cases, however, cBRT and XTT gave discordant results, differing for more than one category. All these cases were referred to C. krusei strains. Further comparative assessment of the two gold- standard methods, CV and XTT, revealed a full categorical agreement in 42 out of 60 (70%) Candida strains, while 15 (25%) showed a partial categorical agreement and in 3 cases (5%), including one C. albicans, one C. parapsilosis and one C. krusei, the results were discordant. The overall concordance among the different techniques was statistically measured by the k coefficient. Results indicated a high level of concordance between cBRT and both CV staining (k = 0.74, P < 0.001) and XTT (k = 0.62), respectively. A good level of concordance was also found between CV and XTT (k = 0.60).
Regarding the quality and strength of biofilm production by Candida strains, a large variation was found between C. albicans and NAC strains (Fig. 3) . The majority of the C. albicans strains were found to be weak biofilm producers, with frequencies varying between 45.8% by XTT and 58.3% by both CV and cBRT. Conversely, the fraction of high biofilm producers was 12.5% by cBRT, 8.3% by CV and 20.0% by XTT.
In the heterogeneous group of NAC, the percentage of weak biofilm producers ranged from 27.8% by CV and XTT to 36.1% by cBRT. This group showed a comparatively higher fraction of moderate and high biofilm producers than C. albicans.
Categorical agreement among the tests was further analyzed for C. albicans and NAC strains (Table 4) . Assessment of C. albicans strains gave a high (k = 0.73) categorical agreement between cBRT and CV and moderate between both cBRT and XTT (k = 0.60), and CV and XTT (k = 0.59), respectively. Conversely, the levels of accordance in the measurement of biofilm were found to be consistently lower when analyzing NAC. Statistical analysis by the Kappa coefficient test revealed a moderate agreement between cBRT and CV (k = 0.65), cBRT and XTT (k = 0.52) and between CV and XTT (k = 0.55), respectively. 
DISCUSSION
This study presents a comparative assessment of biofilm production in Candida species by different methods and describes a novel adaptation of the previously described cBRT, for highthroughput quantification of biofilm production for future application for clinical testing. Eight laboratory strains and 60 clinical isolates were analyzed for their ability to form biofilm. The results gathered by cBRT were compared with those obtained by CV and XTT, respectively, which are considered gold standard screening methods for Candida biofilms (Kuhn et al. 2003; Bizerra et al. 2008; Silva et al. 2009; Melo et al. 2011; Alnuaimi et al. 2013) . All these assays gave comparable results in measuring biofilm formation, showing a high correlation (average measures 0.90-95% confidence interval 0.84 to 0.94), while a full accordance in the assessment of biofilm production was achieved with 68% of the strains analyzed. We found a high overall accordance, between cBRT and both CV (0.74; P < 0.001) and XTT (0.62; P < 0.001), respectively. Specifically, the cBRT showed a higher accordance with the CV staining as compared with the XTT reduction assay. As noted, the cBRT provides a direct physical measurement of the biofilm matrix by evaluating the ability of living Candida cells to entrap magnetic beads within the biofilm (Chavant et al. 2007 ). This represents a major distinction, and an inherent advantage, with respect to the other two techniques, which are based on colorimetric (CV) or metabolic (XTT) endpoints. Indeed, in the XTT reduction assay, XTT is reduced to the XTT formazan product by the mitochondrial dehydrogenases in metabolically active yeast cells. The colorimetric change resulting from this reaction is proportional to the number of living cells within the biofilm and can be quantified (Hawser 1996; Kuhn et al. 2002) . However, this assay cannot directly estimate the real biomass in mature biofilms, since a large proportion of cells embedded in the matrix are known to be in a stationary phase. Nevertheless, XTT remains a widely used assay for measuring biofilm production in Candida species particularly in short time incubation assay. On the other hand, the CV colorimetric technique stains both living and quiescent cells and might offer a more reliable assay to discriminate between low, medium and high biofilm-producing Candida strains. (Hawser et al. 1998; Ramage et al. 2001; Melo et al. 2011; Alnuaimi et al. 2013) . The results of this study suggest a remarkable similarity between CV and cBRT in evaluating the global contribution to biomatrix production by both the metabolically active and inactive cells within the biofilm. In contrast, the XTT reduction assay appears best suited at evaluating antifungal activities on biofilm viability but may not be fully representative of the biofilm matrix production (Jabra-Rizk, Falkler and Meiller 2004; Bizzerra et al. 2008; Melo et al. 2011; Alnuaimi et al. 2013) . The cBRT was found to be highly reliable at assessing biofilm production also on a wide array of different Candida species, including C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei and the relatively more uncommon species of C. dubliniensis, C. famata, C. kefyr and C. lusitaniae. Notably, cBRT showed a higher level of accordance with both CV (k = 0.73) and XTT (k = 0.60) in measuring the level of biofilm production in C. albicans strains with respect to NAC strains (cBRT vs CV-k = 0.65 and cBRT vs XTT-k = 0.52). This result may be the consequence of the large variability in morphology and in the metabolic properties of the different NAC strains analyzed. Biofilm quantification with CV, XTT and cBRT showed that the majority of the C. albicans isolates produced a relatively lower total biomass of biofilm as compared with NAC species. This result support previous studies reporting that NAC have a higher biofilm-forming ability than C. albicans isolated from diverse anatomical sites, including bloodstream, oral cavity and urinary tract (Kumar and Menon 2006; Pathak, Sharma and Shrivastva 2012; Ferreira et al. 2013; Muadcheingka and Tantivitayakul 2015) . These data provide further support to the notion that biofilm formation by Candida strains is a key mechanism to promote colonization and to evade host-defense mechanism particularly in NAC species.
The extensive handling and time-consuming procedures required to perform the CV staining and the XTT reduction assay are generally regarded as a main limitation of these tests, accounting for most intra-and interexperimental variations, which may lead to very large standard deviations (Ramage et al. 2001; Kuhn et al. 2002; Chandra, Mukherjee and Ghannoum 2008; Peeters, Nelis and Coenye 2008; Silva et al. 2009; Nett et al. 2011; Taff, Nett and Andes 2012; Alnuaimi et al. 2013) . Both CV and XTT require repeated washing steps and laborious staining procedures, representing a serious limitation for clinical microbiology applications (Djordjevic, Wiedmann and McLandsborough 2002; Taff, Nett and Andes 2012; Alnuaimi et al. 2013) . Other in vitro techniques to measure biofilms, such as constant depth film fermenters, perfused biofilm fermenters, confocal microscopy, the silicone square biofilm formation test or the microfluidic assay, require specific equipment not common in a clinical laboratory (Douglas 2002; Nobile et al. 2012; Pannanusorn, Fernandez and Römling 2013; Lohse et al. 2017a,b) . Conversely, the cBRT provides a direct physical measurement of the biofilm matrix formation, requires minimal handling and processing and does not need staining procedures. These elements make this test reliable, highly reproducible and suitable for highthroughput screenings.
Further studies are necessary for assay standardization, including the need to further extend the analysis to additional materials and growth media, as well as to broaden the spectrum of Candida species. In fact, growth media can seriously affect adhesion, biofilm production and architecture in Candida species (Serrano-Fujarte et al. 2015; Weerasekera et al. 2016) . However, there is no consensus recommendation for a specific medium suitable for in vitro biofilm assays. In the original cBRT protocol, different growth media were tested and BHI was selected for standardization (Di Domenico et al. 2016) . BHI is commonly used as growth medium also in Candida species (Roberts and Washington 1975) ; thus, to maintain the cBRT protocol as simple as possible, BHI was maintained as the elective standard medium. A further issue with test standardization regards the use of polystyrene microtiter plates. It is plausible that other materials might give different results. Consequently, the cut-off values introduced in this protocol should be considered valid exclusively under the standard conditions tested.
The cBRT assay appears to be a robust, reliable cost-effective assay feasible to high-throughput screenings for quantitative measurement of biofilm formation, thus representing a very promising tool for clinical microbiology. Candida species produce biofilm on different types of implanted medical devices making them relatively refractory to conventional therapy causing high mortality rates (Pappas et al. 2003; Kojic and Darouiche 2004) . The development of methods for the early detection of biofilmproducing Candida species may support a more informed clinical decision and a better therapeutic management of infectionassociated diseases. Identification of high biofilm producing Candida may be used as a specific risk factor to promote an active surveillance in patients considered at high risk for fungal infection.
On the other hand, the simplicity, reliability and low costs of these assays ensures that they will be feasible for a rapid translation into clinical applications, representing novel key tools to incorporate into the routine testing of clinical laboratories.
